1. Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment

2. Learning Objectives

3. Patient Presentation

4. Intensive Statin Therapy: Residual CV Risk

5. Efficacy of Fibrates in Small Trials

6. Comparison of ACCORD Subgroup Results With Those from Prior Fibrate Studies

7. Comparison of ACCORD Subgroup Results With Those From Prior Fibrate Studies

8. Efficacy of Niacin

9. Coronary Drug Project: Clinical Outcomes

10. AIM-HIGH: End Point at 36-month Follow-up

11. Effect of Niacin on Major Vascular Events

12. Patient Presentation

13. PPAR- γ: Lipoprotein Effects of Pioglitazone in T2DM

14. SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2D

15. ALECARDIO: Aleglitazar in Patients With T2D and ACS*

16. Abbreviations (cont)

17. Abbreviations

18. References

19. References (cont)